RLAY News and Press, Relay Therapeutics Inc. From 09/12/22

Medicine company Relay Therapeutics ( NASDAQ: RLAY ) has commenced an underwritten public offering of $300M shares. Additionally, the underwriters can also be granted a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. RLAY...

88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023 Relay...

The shares of the clinical stage biotech Relay Therapeutics, Inc. ( NASDAQ: RLAY ) fell on Friday after an announcement of an abstract containing Phase 1/2 data for its bile duct cancer therapy RLY-4008 sent company shares sharply higher a day earlier. With data suggesting...

The shares of the clinical-stage biotech Relay Therapeutics, Inc. ( NASDAQ: RLAY ) added more than 19% in the morning hours Thursday after the company announced the publication of an abstract containing data from its Phase 1/2 study for bile duct cancer therapy RLY-4008....

CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that a late breaking ab...

Relay Therapeutics press release ( NASDAQ: RLAY ): Q2 GAAP EPS of -$0.71. Revenue of $0.37M. For further details see: Relay Therapeutics GAAP EPS of -$0.71, revenue of $0.37M

Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June 27 th analyst and investor event CAMBRIDGE, Mass., Aug. 04, 2...

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2022 fin...

Gainers: Evofem Biosciences (EVFM) +172%. Acutus Medical (AFIB) +97%. NeuroSense (NRSN) +52%. Axsome (AXSM) +42%. Clene (CLNN) +35%. AeroClean (AERC) +28%. Femasys (FEMY) +30%. Scholar Rock Holding (SRRK) +22%. Precision Bio Sciences (DTIL) +20%. Boxed (BOXD) +19%. Losers: Powerbridge Technol...

Relay Therapeutics (NASDAQ:RLAY) will forge ahead with a single arm trial design for RLY-4008 for cholangiocarcinoma ("CCA"), also known as bile duct cancer. The company said it will examine FGFRi-naïve FGFR2-fusion CCA at 70 mg once daily in the hopes of an accelerated approval in a mid...